42 patents
Utility
Actriib Binding Agents and Uses Thereof
31 Mar 22
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
Ravindra Kumar, Asya Grinberg, Monique Davies, Diana Martik, Janja Cosic, Rachel Kent, David Buckler
Filed: 30 Apr 21
Utility
Evacuated Blood Collection Tubes Containing Protease Inhibitors for the Assessment of Contact System Activation
21 Oct 21
Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
Daniel J. Sexton, Ryan Faucette
Filed: 24 Nov 20
Utility
FC Receptor Binding Proteins
7 Oct 21
The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
Filed: 17 Mar 21
Utility
Protein Biomarkers for Diseases Associated with the Contact Activation System
16 Sep 21
Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
Filed: 15 Sep 17
Utility
Immunoassay to Detect Cleaved High Molecular Weight Kininogen
2 Sep 21
The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
Daniel J. Sexton, Ryan Faucette, Janja Cosic
Filed: 5 Jan 21
Utility
Antibodies Against Phosphorylcholine
5 Aug 21
Knut PETTERSSON, Ola CAMBER, Dan SEXTON, Andrew E. NIXON
Filed: 13 Apr 21
Utility
Monoclonal Antibody Inhibitor of Factor Xiia
29 Jul 21
Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
Filed: 29 Dec 20
Utility
Antibodies Binding to Phosphorylcholine (PC) And/or PC Conjugates
29 Jul 21
Knut PETTERSSON, Ola CAMBER, Dan SEXTON, Andrew E. NIXON
Filed: 13 Apr 21
Utility
Compositions and methods for treatment of diabetic macular edema
29 Jun 21
Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.
Gregory P. Conley, Andrew Nixon, Daniel J. Sexton
Filed: 15 Aug 19
Utility
Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
25 May 21
The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
Daniel J. Sexton, Christopher TenHoor, Malini Viswanathan
Filed: 7 Oct 19
Utility
Novel Methods of Constructing Libraries Comprising Displayed And/or Expressed Members of a Diverse Family of Peptides, Polypeptides or Proteins and the Novel Libraries
25 Mar 21
Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods.
Robert Charles Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
Filed: 4 Aug 20
Utility
Plasma Kallikrein Binding Proteins and Uses Thereof In Treating Hereditary Angioedema
25 Mar 21
Provided herein are plasma kallikrein binding proteins such as antibodies binding to active plasma kallikrein and methods of using such proteins in treating hereditary angioedema.
Daniel J. Sexton, Burt Adelman, Yung Chyung, Christopher TenHoor, Jon A. Kenniston, Ryan Faucette, Ryan Iarrobino, Joseph Biedenkapp
Filed: 2 Sep 20
Utility
Monoclonal antibody inhibitor of factor XIIA
9 Feb 21
Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.
Shauna Mason, Jon A. Kenniston, Andrew Nixon, Daniel J. Sexton, Stephen R. Comeau, Burt Adelman
Filed: 21 Jul 16
Utility
Immunoassay to detect cleaved high molecular weight kininogen
9 Feb 21
The present disclosure provides immunoassay methods of detecting a cleaved high molecular weight kininogen (HMWK) with high sensitivity and specificity and isolated antibodies that specifically bind cleaved HMWK.
Daniel J. Sexton, Ryan Faucette, Janja Cosic
Filed: 19 Oct 16
Utility
Peptide Quantitation Assay for Differentiating Full-length High Molecular Weight Kininogen (HMWK) and Cleaved HMWK
28 Jan 21
Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein.
Jiang Wu, Guodong Zhang, Daniel J. Sexton, Ryan Faucette, Gul M. Mustafa, Mark Szewc
Filed: 15 Dec 16
Utility
Libraries of Genetic Packages Comprising Novel HC CDR3 Designs
23 Dec 20
Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme.
Robert Charles Ladner
Filed: 8 Jun 20
Utility
Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
21 Dec 20
Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.
Daniel J. Sexton, Ryan Faucette
Filed: 11 Aug 16
Utility
Evaluation, Assays and Treatment of Pkal-mediated Disorders
16 Dec 20
The invention provides assay methods of detecting last protease CI inhibitor (C1-INH) that binds plasma kallikreir, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder.
Kusumam Joseph, Allen P. Kaplan
Filed: 21 May 20
Utility
Diagnosis and Treatment of Autoimmune Diseases
25 Nov 20
Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.
Daniel J. Sexton, Burt Adelman, Andrew Nixon
Filed: 14 Apr 20
Utility
Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
9 Nov 20
Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods.
Robert Charles Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
Filed: 1 Jun 17